Premenstrual Syndrome Treatment Market Report and Forecast 2025-2034

The premenstrual syndrome treatment market is experiencing steady growth, driven by rising awareness and demand for effective therapies. With an increasing focus on women’s health, the market growth is expected to be fuelled by advancements in hormonal and non-hormonal treatments aimed at alleviating distressing symptoms associated with premenstrual syndrome.

Growing concerns about women’s health have led to increased research into effective therapies. As more women seek medical support for managing premenstrual discomfort, healthcare providers and pharmaceutical companies are investing in innovative solutions to improve patient outcomes and enhance overall well-being.

Premenstrual syndrome (PMS) is a common condition affecting women during the luteal phase of their menstrual cycle, leading to both physical and emotional symptoms. Severe cases of PMS can interfere with daily life, necessitating appropriate treatment. Common symptoms include bloating, mood swings, fatigue, and headaches, which arise due to hormonal fluctuations during menstruation. Advancements in therapeutic interventions are improving the management of these symptoms, allowing women to maintain a better quality of life throughout their menstruation cycles.

Various treatment options are available for PMS, including hormonal contraceptives, antidepressants, analgesics, and NSAIDs to relieve symptoms. OTC medicines like pain relievers help with mild discomfort, while prescription medications manage severe cases. Some drugs, including cannabidiol, offer alternative relief. Additionally, treatments targeting ovarian function regulation are gaining traction, providing effective solutions for PMS sufferers seeking long-term management.

Premenstrual Syndrome Treatment Market Growth Factors

Rising Incidence of PMS

The increasing occurrence of premenstrual syndrome (PMS) and its severe form, premenstrual dysphoric disorder (PMDD), is a major driver of market growth. A global study involving over 50,000 women found that approximately 1.6%, equating to 31 million women and girls, experience symptomatic PMDD. This rising prevalence, particularly among women of reproductive age, has heightened the demand for effective treatments. As PMS symptoms significantly impact daily life, healthcare providers are focusing on advanced therapies to improve symptom management. The growing awareness and diagnosis of PMS and PMDD are accelerating research efforts, leading to a broader range of targeted medications, hormonal treatments, and lifestyle interventions to address these conditions.

Rising Awareness of PMS Treatment Options

Increasing awareness of PMS and its severe form, PMDD, has played a vital role in driving market expansion. Organizations such as the International Association for Premenstrual Disorders (IAPMD) actively promote PMS awareness through initiatives like the "Our Lightbulb Moment" campaign in 2024. This campaign encouraged individuals to share their realisations about PMS and PMDD, urging healthcare providers and policymakers to prioritise women’s health. Such awareness movements help break stigma, encourage early diagnosis, and promote available therapeutic options. As more women seek medical support, the demand for advanced PMS treatments continues to grow. Educational initiatives and advocacy efforts are expected to further drive market growth by ensuring that women have access to necessary healthcare solutions.

Market Restraint

Limited Demand in Developing and Low-Income Regions

Despite the increasing global awareness of PMS treatments, underdeveloped countries face significant challenges in addressing this condition due to limited healthcare access, economic constraints, and social stigma. In many regions, women lack proper diagnosis and treatment options due to inadequate medical infrastructure and minimal government initiatives for women’s health. Additionally, cultural taboos surrounding menstruation discourage many women from seeking medical support, further hindering market growth. The lack of awareness about PMS and available therapeutic interventions also contributes to lower demand. Pharmaceutical companies often hesitate to introduce advanced PMS treatments in these markets due to low affordability and poor healthcare coverage. To overcome these barriers, targeted awareness campaigns, governmental health programs, and increased funding for reproductive health are essential. Addressing these issues could help expand market reach and improve PMS treatment accessibility in low-income regions.

Premenstrual Syndrome Treatment Market Opportunities

Addressing Unmet Needs with Innovative Treatment Solutions

The market presents substantial opportunities due to the large number of unmet medical needs. Many women worldwide struggle with severe PMS symptoms, yet effective treatment options remain limited. While hormonal contraceptives, antidepressants, and analgesics are commonly used, they do not work universally, creating a demand for more targeted solutions. Additionally, the lack of FDA-approved drugs specifically for premenstrual syndrome leaves a gap in the market for innovative therapeutic options. Advances in personalised medicine, including non-hormonal treatments and alternative therapies such as cannabidiol-based drugs, offer new growth potential. Pharmaceutical companies investing in novel drug formulations and expanding clinical research for PMS-specific treatments can capitalise on this demand. Increasing focus on ovarian function regulation and natural remedies further supports the need for diverse treatment options, making this a lucrative opportunity for market expansion.

Regional Insights

United States PMS Treatment Market

The United States leads the premenstrual syndrome (PMS) treatment market due to high healthcare expenditure, strong pharmaceutical research, and increasing awareness. The rising prevalence of PMS and premenstrual dysphoric disorder (PMDD), coupled with the availability of advanced treatment options, supports market growth. Favorable regulatory policies further enhance accessibility to PMS therapeutics.

United Kingdom PMS Treatment Market

In the UK, growing awareness campaigns and improved access to healthcare services drive the PMS treatment market. Government initiatives and research funding for women’s health encourage innovation. The increasing adoption of over-the-counter (OTC) medications and hormonal contraceptives for PMS symptom relief also contribute to market expansion in the region.

Germany PMS Treatment Market

Germany’s advanced pharmaceutical industry and strong healthcare infrastructure make it a key player in the PMS treatment market. Increasing research on hormonal therapies and natural remedies boosts growth. Additionally, rising awareness among women about available therapeutic options and expanding insurance coverage for PMS treatments contribute to market development.

France PMS Treatment Market

France is witnessing steady growth in the market due to increasing demand for prescription and OTC medications. The country’s emphasis on women’s health awareness and availability of alternative therapies, including herbal and cannabidiol-based treatments, further support market expansion. Regulatory policies also ensure accessibility to a wide range of treatments.

Italy PMS Treatment Market

The Italian market is driven by rising healthcare awareness and the adoption of integrative medicine. A growing preference for dietary supplements, homeopathic remedies, and NSAIDs for PMS symptom management influences market trends. Supportive government healthcare initiatives and reimbursement policies enhance patient access to effective treatment options.

Spain PMS Treatment Market

In Spain, growing awareness about the condition and increasing diagnosis rates contribute to market growth. The availability of diverse treatment options, including hormonal contraceptives and antidepressants, supports demand. Public health campaigns and women’s wellness initiatives further drive the adoption of both conventional and alternative treatments for PMS management.

Japan PMS Treatment Market

Japan’s treatment market benefits from advancements in pharmaceutical research and a high focus on women’s healthcare. The country’s preference for natural and holistic remedies, including herbal medicine and acupuncture, complements conventional treatment options. Additionally, increasing workplace wellness programs addressing PMS symptoms contribute to market expansion.

India PMS Treatment Market

India is witnessing growing demand for PMS treatments due to rising awareness and changing healthcare perceptions. The increasing availability of OTC medications, combined with traditional Ayurvedic and herbal remedies, fuels market growth. Expanding healthcare infrastructure and government initiatives promoting women’s health further support the development of the PMS treatment market.

Segmental Analysis

By Drug Type

Analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen, are widely used to relieve PMS symptoms such as cramps and headaches. Their affordability and availability as over-the-counter (OTC) options make them a preferred choice. Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), are prescribed for severe PMS and premenstrual dysphoric disorder (PMDD). These drugs help regulate mood swings, anxiety, and depression associated with hormonal fluctuations.

Oral contraceptives and ovarian suppression agents are gaining traction due to their ability to stabilize hormonal imbalances and alleviate PMS symptoms. These drugs regulate estrogen and progesterone levels, reducing physical and emotional discomfort. Additionally, emerging drug formulations, including combination therapies and novel hormonal treatments, are expanding treatment options. Growing research in personalized medicine is expected to drive further advancements in this segment.

By Type

Prescription drugs dominate the market, particularly for severe cases requiring medical supervision. Antidepressants, hormonal therapies, and advanced formulations fall into this category. Physicians increasingly recommend prescription treatments for PMDD and severe PMS, as these drugs offer long-term relief and are backed by clinical research. Growing awareness of evidence-based treatments is boosting their demand.

Over-the-counter (OTC) drugs, including NSAIDs, herbal supplements, and vitamins, account for a significant market share. Many women prefer OTC solutions for mild to moderate PMS symptoms due to their easy accessibility and affordability. Natural and alternative remedies, such as evening primrose oil and magnesium supplements, are also gaining popularity as non-prescription options for symptom management.

By Distribution Channel

Hospital pharmacies play a significant role in PMS treatment distribution, particularly for prescription medications like hormonal contraceptives and antidepressants. Patients visiting hospitals for diagnosis and treatment rely on these pharmacies for expert guidance. Moreover, retail pharmacies remain a dominant distribution channel, offering both prescription and OTC drugs.

Online pharmacies are witnessing substantial growth due to increasing digitalisation and consumer preference for convenience. E-commerce platforms provide a broad range of PMS medications, including pain relievers and supplements, often at competitive prices. Additionally, home delivery services and telehealth consultations further boost online pharmacy adoption in PMS treatment.

List of Key Players in Premenstrual Syndrome Treatment Market 

Other key players in the market include GlaxoSmithKline Plc, H. Lundbeck A/S, MetP Pharma AG, Bayer AG, BASF Corporation, Dr. Reddy’s Laboratories Ltd, Shionogi Inc., and AstraZeneca plc.

Recent Developments

• In January 2025, ASKA Pharmaceutical and SUSMED launched a clinical trial to evaluate a digital therapeutics app for PMS and PMDD patients. Conducted in collaboration with Fukushima Medical University, the study aims to assess the app’s effectiveness and safety, offering a novel, technology-driven approach to managing premenstrual disorders.
• In July 2024, researchers explored neurosteroids as potential treatments for PMDD, following the success of brexanolone and zuranolone in postpartum depression. A study investigated whether selective serotonin reuptake inhibitors (SRIs) impacts neurosteroid levels, potentially improving PMDD symptoms. Participants received 50 mg sertraline during the luteal phase to assess its effects.
• In October 2024, Clue, a menstrual health tracking app, unveiled a groundbreaking study linking gastrointestinal symptoms, mood, and menstrual cycles. Conducted by the Johns Hopkins University, it analysed over 33,000 cycles from 32,000 participants, highlighting the intricate relationship between menstrual health and digestive well-being in PMS sufferers.
• In May 2021, Power Gummies introduced ‘That Time of The Month Gummies,’ a dietary supplement designed to support menstrual and hormonal health. The product aims to help women manage PMS symptoms naturally, reinforcing the growing demand for innovative, consumer-friendly solutions in women's health and wellness.

Premenstrual Syndrome Treatment Market Segmentations